Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC09/ritonavir vs Lopinavir/ritonavir in COVID-19 Pneumonia
NCT04261907Terminated
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of TMC-310911 in COVID-19 pneumonia, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Incidence of composite adverse outcome at 14 days. Started Feb 2020; status: terminated.
02
Drugs
TMC-310911
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04261907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261907.